2-Oct-2026
PRNewswire (Thu, 6-Aug 11:02 PM ET)
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 30-Jul 6:30 AM ET)
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Globe Newswire (Tue, 21-Jul 7:00 AM ET)
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
Globe Newswire (Tue, 7-Jul 7:00 AM ET)
Mitapivat Revenues More Than Double: Agios' Thalassemia Launch Drives Strong Q1 Growth in 2026
Market Chameleon (Wed, 29-Apr 7:46 AM ET)
Market Chameleon (Wed, 24-Dec 5:33 AM ET)
FDA Approves Agios’ AQVESME as First and Only Therapy for Anemia in Both Alpha- and Beta-Thalassemia
Market Chameleon (Wed, 24-Dec 2:32 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of October 2, 2026, AGIO stock price declined to $31.80 with 529,074 million shares trading.
AGIO has a beta of 2.11, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.10 to the broad based SPY ETF.
AGIO has a market cap of $1.90 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $45 million in Revenue and -$1.69 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.02.
In the last 3 years, AGIO traded as high as $62.58 and as low as $19.80.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): VTI, XBI, IWM, VB, VBK.
AGIO has underperformed the market in the last year with a price return of -20.4% while the SPY ETF gained +16.1%. AGIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.4% and -3.8%, respectively, while the SPY returned +3.6% and +1.0%, respectively.
AGIO support price is $31.61 and resistance is $33.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO shares will trade within this expected range on the day.
